MAZDUTIDE 10MG - PeptideNova

Save 20% + FREE Shipping on Orders $175+ — Use Code “HEALTH20” Before 7/27

MAZDUTIDE 10MG

QUALITY YOUR CAN TRUST

All peptides are tested for purity and identity.

RESEARCH USE ONLY

For laboratory research purposes only.

FREE Shipping

On all orders over $150 delivered within the U.S.A.

Bulk Orders

As a top research supplier, we can meet any quantity demand.

RESEARCH PEPTIDES

MAZDUTIDE 10MG

Product Name: Mazdutide
Product Code: MAZ-10MG
Batch Number: BT2505MAZ
Catalog Number: RC-MAZ-10MG
Strength: 10MG
CAS Number: 2259884-03-0
Molecular Formula: Referenced in scientific literature (peptide analog structure)
Molecular Weight: Referenced in literature (approximate, based on analog design)
Amino Acid Sequence: Referenced in scientific literature (synthetic peptide analog)
Peptide Classification: Synthetic signaling peptide analog (incretin receptor dual agonist class)
Form: Lyophilized Powder

Original price was: $189.99.Current price is: $158.99.

ANALYTICAL SPECIFICATIONS

Purity (HPLC)

≥99%

Identity (LC-MS)

Conforms

Solubility

36–46°F (2–8°C)

Storage

Store refrigerated at 2–8°F in a dry environment

COA

Available upon request

BULK INQUIRES

Contact us for bulk pricing and custom research requirement.

Links To Research Studies

Mazdutide demonstrated robust HbA1c reduction and significant weight loss in Chinese patients with type 2 diabetes in a Phase 2 randomized controlled trial, confirming both glycemic and metabolic benefits

A 24-week Phase 2 trial of Mazdutide up to 6 mg in overweight and obese adults showed dose-dependent weight loss up to 11% and strong safety, marking it as a leading dual GLP‑1/glucagon receptor agonist candidate

Phase 3 DREAMS‑2 study results revealed Mazdutide’s superiority over dulaglutide in glycemic control, weight reduction, and cardiometabolic improvements in Chinese patients with type 2 diabetes

China’s NMPA approved Mazdutide, the first dual GLP‑1/glucagon receptor agonist for chronic weight management, offering dual fat‑burning and metabolic enhancement benefits

ADA 2024 abstract: Mazdutide significantly reduced body weight and liver steatosis while improving cardiometabolic parameters in overweight and obese patients

ADA 2024 abstract: Mazdutide demonstrated marked efficacy and safety in obese and overweight Chinese adults, achieving meaningful metabolic and hepatic benefits

Recent meta‑analysis confirmed Mazdutide’s dual‑agonist mechanism significantly improves glucose regulation and induces superior body‑weight reductions compared with other GLP‑1 therapies

Extended Phase 3 and metabolic trials of Mazdutide continue to highlight its potential as a first‑in‑class dual incretin therapy for obesity and diabetes management worldwide

Links To Research Studies

Mazdutide demonstrated robust HbA1c reduction and significant weight loss in Chinese patients with type 2 diabetes in a Phase 2 randomized controlled trial, confirming both glycemic and metabolic benefits

A 24-week Phase 2 trial of Mazdutide up to 6 mg in overweight and obese adults showed dose-dependent weight loss up to 11% and strong safety, marking it as a leading dual GLP‑1/glucagon receptor agonist candidate

Phase 3 DREAMS‑2 study results revealed Mazdutide’s superiority over dulaglutide in glycemic control, weight reduction, and cardiometabolic improvements in Chinese patients with type 2 diabetes

China’s NMPA approved Mazdutide, the first dual GLP‑1/glucagon receptor agonist for chronic weight management, offering dual fat‑burning and metabolic enhancement benefits

ADA 2024 abstract: Mazdutide significantly reduced body weight and liver steatosis while improving cardiometabolic parameters in overweight and obese patients

ADA 2024 abstract: Mazdutide demonstrated marked efficacy and safety in obese and overweight Chinese adults, achieving meaningful metabolic and hepatic benefits

Recent meta‑analysis confirmed Mazdutide’s dual‑agonist mechanism significantly improves glucose regulation and induces superior body‑weight reductions compared with other GLP‑1 therapies

Extended Phase 3 and metabolic trials of Mazdutide continue to highlight its potential as a first‑in‑class dual incretin therapy for obesity and diabetes management worldwide

LABORATORY ONLY

All products are intended for in vitro research applications in laboratory settings.

CERTIFICATE OF ANALYSIS

Detailed COA’s for all products available upon request

QUALITY ASSURED

Rigorous testing ensures consistency. purity. and reliability.

SECURE SHIPPING

Shipping with tracking number provided for every shipment.

Related Products

RETA 15MG

Original price was: $289.99.Current price is: $169.99.

CJC-1295 NO DAC 2MG

Original price was: $49.99.Current price is: $34.99.

AICAR 50MG

$59.99

ACE-031 1MG

$164.99